Investment of $35 million Supports “Boston Oncology Arabia” in Providing Biopharmaceuticals in Saudi Arabia
TVM Capital Healthcare, specializing in global healthcare capital investments, has announced a $35 million investment in the biotechnology company “Boston Oncology Arabia”. Based in Saudi Arabia, Boston Oncology Arabia leverages extensive expertise in biopharmaceutical manufacturing, offering advanced solutions for critical conditions through modern technology and globally approved raw materials.
This move reflects TVM Capital Healthcare’s commitment to supporting innovation and enhancing healthcare infrastructure in the region, thereby bolstering Boston Oncology Arabia’s capabilities to expand production and access new international markets. The investment aligns with Saudi Arabia’s Vision 2030, aiming to promote sustainability and achieve comprehensive development through innovative healthcare initiatives.
Dr. Abdullah Baaj, Founder and CEO of Boston Oncology Arabia, expressed optimism about the company’s future with this strategic support, emphasizing their dedication to providing advanced, internationally accredited medical solutions to patients within and beyond the region.
Dr. Helmut M. Schuehsler, Chairman and CEO of TVM Capital Healthcare, praised the close collaboration between the two companies, underscoring the importance of strategic partnerships in promoting innovation and achieving excellence in the healthcare sector across the Middle East and North Africa.
With this investment, Boston Oncology Arabia is poised for a new phase of growth and expansion, leveraging global expertise and resources available through TVM Capital Healthcare’s network to further advance biopharmaceutical manufacturing and supply in global markets.
